{
  "docId": "019de075-e6e6-7212-9fa1-8acb312e82f0",
  "docSlug": "a6ecebb143ed44be24e72b777fff8cb3",
  "documentTitle": "argenx SE | Results Presentation Deck | 14 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 14,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide outlines a randomized clinical trial structure.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e6e6-7212-9fa1-8acb312e82f0/6",
  "deckHref": "/decks/019de075-e6e6-7212-9fa1-8acb312e82f0",
  "deckJsonHref": "/decks/019de075-e6e6-7212-9fa1-8acb312e82f0.json",
  "deckAnchorHref": "/decks/019de075-e6e6-7212-9fa1-8acb312e82f0#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.25,
        "y": 0.085
      },
      "kind": "callout",
      "text": "Topline data expected around YE 2023",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2935a3cc-20cb-41b4-937a-a89025125dd7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.75,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Trial flow from screening to randomization and treatment arms",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b62a0f46-25d1-4010-9e85-427acaad09a8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.15,
        "x": 0.8,
        "y": 0.02
      },
      "kind": "image",
      "text": "address pemphigus study logo",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afc2492c-0260-4c05-8a3a-de7c18d24259",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.18,
        "x": 0.8,
        "y": 0.3
      },
      "kind": "list",
      "text": "Primary endpoint is proportion of PV patients achieving CRmin* within 30 weeks; N=222 (PV and PF); PF patients capped; Followed by Open Label Extension study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41a42ab9-cab8-42a8-ac3e-79bdeae77fbf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.5,
        "x": 0.03,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "CR=complete clinical remission; CRmin=complete remission on minimal therapy; EoC=end of consolidation; SC=subcutaneous.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5137107b-632b-4ce1-a532-69e4f2226734",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Pemphigus ADDRESS Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1106a13-e482-4915-a2ac-95f710e34481",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "4c992234-50f8-404f-bde0-2f5ed8eacbec",
      "evidence": "Primary endpoint is proportion of PV patients achieving CRmin* within 30 weeks; N=222 (PV and PF);",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "5c16bda4-b835-4ced-a541-25cea69ca3a8",
      "evidence": "The slide maps out the phases of a clinical trial (screening, randomization, treatment arms, endpoints).",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}